Themes the Blue Ribbon Panel will discuss in the coming months:
- cancer vaccines
- highly sensitive approaches to early detection
- advances in immunotherapy and combination therapies
- single cell genomic profiling of cancer cells and cells in the tumor microenvironment
- enhanced data sharing
- new approaches to treating pediatric cancers
The Blue Ribbon Panel as announced on April 4th 2016:
|Tyler Jacks, Ph.D. (Co-Chair)|
|Chair, National Cancer Advisory Board, and Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge|
|Elizabeth Jaffee, M.D. (Co-Chair)|
|Professor and Deputy Director for Translational Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore|
|Dinah Singer, Ph.D. (Co-Chair)|
|Acting Deputy Director and Division of Cancer Biology Director, National Cancer Institute, Bethesda, Maryland|
|Peter Adamson, M.D.|
|Professor and Director, Experimental Therapeutics in Oncology, The Childrenâ€™s Hospital of Philadelphia|
|James Allison, Ph.D.|
|Professor and Chair of Immunology, University of Texas MD Anderson Cancer Center, Houston|
|David Arons, J.D.|
|Chief Executive Officer, National Brain Tumor Society, Newton, Massachusetts|
|Mary Beckerle, Ph.D.|
|CEO and Director, Huntsman Cancer Institute, Salt Lake City|
|Mitch Berger, M.D.|
|Professor and Chair, Department of Neurological Surgery, University of California, San Francisco|
|Jeff Bluestone, Ph.D.|
|A.W. And Mary Margaret Clausen Distinguished Professor, University of California, San Francisco|
|Mikael Dolsten, M.D., Ph.D.|
|President, Pfizer Worldwide Research and Development, and Executive Vice President, Pfizer, Inc., New York City|
|James Downing, M.D.|
|President and CEO, St. Jude Childrenâ€™s Research Hospital, Memphis, Tennessee|
|Levi Garraway, M.D., Ph.D.|
|Associate Professor of Medicine, Harvard Medical School, and Assistant Professor of Medicine, Dana-Farber Cancer Institute, Boston|
|Gad Getz, Ph.D.|
|Director, Cancer Genome Computational Analysis and Institute Member, Broad Institute, Director, Bioinformatics Program, MGH Cancer Center and Department of Pathology, Associate Professor of Pathology, Harvard Medical School, Paul C. Zamecnik Chair in Oncology, MGH Cancer Center|
|Laurie Glimcher, M.D.|
|Professor of Medicine and Dean, Weill Cornell Medical College, and Incoming President and CEO, Dana-Farber Cancer Institute, Boston|
|Lifang Hou, M.D., Ph.D.|
|Associate Professor of Preventive Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago|
|Neal Kassell, M.D.|
|Professor of Neurosurgery, University of Virginia, Charlottesville|
|Maria Elena Martinez, Ph.D.|
|Professor of Family Medicine and Public Health, Reducing Cancer Disparities Program, UC San Diego Moores Cancer Center|
|Deborah Mayer, Ph.D., R.N.|
|Professor of Adult and Geriatric Health, University of North Carolina School of Nursing, and Director of Cancer Survivorship, UNC Lineberger Comprehensive Cancer Center, Chapel Hill|
|Edith Mitchell, M.D., F.A.C.P|
|Professor of Medical Oncology and Associate Director for Diversity Services, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia|
|Augusto Ochoa, M.D.|
|Professor of Pediatrics and Director, Stanley S. Scott Cancer Center, Louisiana State University, New Orleans|
|Jennifer Pietenpol, Ph.D.|
|Professor of Oncology, Professor of Biochemistry, and Director, Vanderbilt-Ingram Cancer Center, Nashville|
|Angel Pizarro, M.S.E.|
|Technical Business Development Manager, Amazon Web Services Scientific Computing and Research Computing, Philadelphia|
|Barbara Rimer, Dr.P.H.|
|Alumni Distinguished Professor and Dean, University of North Carolina Gillings School of Global Public Health, Chapel Hill|
|Charles Sawyers, M.D.|
|Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, and Investigator, Howard Hughes Medical Institute, New York City|
|Ellen Sigal, Ph.D.|
|Founder and Chair, Friends of Cancer Research, Washington, D.C.|
|Patrick Soon-Shiong, M.B.B.Ch.|
|Founder, Chair, and CEO, NantWorks LLC, Los Angeles|
|Chi Van Dang, M.D., Ph.D.|
|Professor of Medicine and Director, Abramson Cancer Center, University of Pennsylvania, Philadelphia|
|Wai-Kwan Alfred Yung, M.D.|
|Professor of Neuro-Oncology and holder of the Margaret and Ben Love Chair of Clinical Cancer Care, University of Texas MD Anderson Cancer Center, Houston|
What Is the Blue Ribbon Panel?
The National Cancer Institute of the NIH announced the Blue Ribbon Panel: the scientific experts, cancer leaders, and patient advocates that will inform the scientific goals and direction of the National Cancer Moonshot Initiative, which was established in the January 12, 2016 State of the Union Address by President Barack Obama and is led by Vice President Joe Biden. The goals: make more therapies available to patients, improve cancer preventative and detection methods.
How Will It Work?
- 1) A forum will be established for the cancer community to post to, as well as the American public, to help inform the Blue Ribbon Panel deliberations.
- 2) The Bue Ribbon Panel's reports will be given to the National Cancer Advisory Board (NCAB)
- 3) The NCAB will review and make recommendations to NCI and contribute to the overall approach of the initiative.
NCI Acting Director Douglas Lowy, M.D. said, The goal of the Moonshot Initiative is to accelerate progress in the fight against cancer by swiftly advancing knowledge from cutting-edge basic research to new prevention and treatment strategies for patients, He continued to say, The community involvement that the initiative garners will allow us to consider novel, creative ideas that might not otherwise have come to NCIs attention.
This feedback platform is just one of the ways the public can provide ideas for accelerating progress in the fight against cancer through this initiative. Ideas can also be submitted by email (send to: firstname.lastname@example.org), or by calling the Cancer Information Service at 1-800-4-CANCER.
To receive updates on the online platform and other aspects of the National Cancer Moonshot Initiative, please visit the initiatives main website.
The National Cancer Institute leads the National Cancer Program. The NIHs efforts are to dramatically reduce cancer prevalence and to improve lives of cancer patients and their families through research into prevention and cancer biology, development of new interventions, and the training and mentoring of new researchers. To know more about cancer, please visit the NCI website at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER.